Wall Street analysts change outlook on top names. Check out analyst ratings page for upgrades, downg

WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committ

Stifel analyst Annabel Samimy initiates coverage on EyePoint (NASDAQ:EYPT) with a Buy rating and

Globally renowned retina specialist and key opinion leader to provide strategic guidance across clin

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Cantor Fitzgerald analyst Steve Seedhouse assumes EyePoint (NASDAQ:EYPT) with a Overweight rating

Chardan Capital analyst Andreas Argyrides maintains EyePoint (NASDAQ:EYPT) with a Buy and raises

Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near t

WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committ

EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc

Eyepoint Pharmaceuticals NASDAQ: EYPT executives said the company remains on track to report top-lin

WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committe

WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committe

– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after –  – Continu

EyePoint is rated a clear BUY, with central-case DCF modeling indicating roughly 2x upside from curr

RBC Capital analyst Lisa Walter maintains EyePoint (NASDAQ:EYPT) with a Outperform and lowers the

EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript

EyePoint (EYPT) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimat

WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committe

WATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company commit

Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 sh

WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company commit

Aberdeen Group plc boosted its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) by 101.6% i

Executives from Eyepoint Pharmaceuticals (NASDAQ: EYPT) told investors at RBC Capital Markets' Ophth

On March 20, 2026, EyePoint, Inc. (the "Company") filed a complaint against Ocular Therapeut

WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committ

Parkman bought 1,088,033 shares of EyePoint in the fourth quarter, marking a new stake for the fund.

Citigroup analyst Yigal Nochomovitz maintains EyePoint (NASDAQ:EYPT) with a Buy and raises the pr

Summary:Top Wall Street analysts changed outlook on top names. Analyst ratings page shows all chang

HC Wainwright & Co. analyst Yi Chen maintains EyePoint (NASDAQ:EYPT) with a Buy and raises th

Chardan Capital analyst Daniil Gataulin maintains EyePoint (NASDAQ:EYPT) with a Buy and raises th

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.81) per share which missed t

– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retin

– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal

  On Thursday, 241 companies hit new 52-week lows.

Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i

  During Wednesday's trading, 517 companies set new 52-week lows.

  On Friday, 404 stocks made new 52-week lows.

  Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua